Delivery of BMP-2 by two clinically available apatite materials: In vitro and in vivo comparison

Journal of Biomedical Materials Research - Part A

Volumn 103, Issue 2, 2015, Pages 628-638

  Hänseler, Patrick ^a,b   Ehrbar, Martin ^c   Kruse, Astrid ^a,b   Fischer, Eliane ^d   Schibli, Roger ^d   Ghayor, Chafik ^a,b   Weber, Franz E ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d ETH Zurich   (Switzerland)

Author keywords

BMP; bone morphogenetic protein; bone regeneration; bone substitute; delivery; release system

Indexed keywords

APATITE; GRANULATION; PHOSPHATE MINERALS; PROTEINS;

BMP; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; BONE SUBSTITUTES; DELIVERY; RELEASE SYSTEM;

BONE;

APATITE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM PHOSPHATE; HYDROXYAPATITE; BETA-TRICALCIUM PHOSPHATE; BMP2 PROTEIN, HUMAN; BONE PROSTHESIS; DELAYED RELEASE FORMULATION;

ANIMAL EXPERIMENT; ARTICLE; BONE MATRIX; BONE PROSTHESIS; BONE REGENERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN PROTEIN INTERACTION; ANIMAL; BOVINE; CHEMISTRY; DELAYED RELEASE FORMULATION; PHARMACOKINETICS; PHARMACOLOGY; RABBIT;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE SUBSTITUTES; CALCIUM PHOSPHATES; CATTLE; DELAYED-ACTION PREPARATIONS; DURAPATITE; HUMANS; RABBITS;

EID: 84924402092     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.35211     Document Type: Article

References (32)

1. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA,. Novel regulators of bone formation: Molecular clones and activities. Science 1988; 242: 1528-1534.
2. Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, White KH, Coughlin JE, Tucker MM, Pang RH, Corbett C, Ozkaynak E, Oppermann H, Rueger DC,. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992; 267: 20352-20362.
3. Wildemann B, Burkhardt N, Luebberstedt M, Vordemvenne T, Schmidmaier G,. Proliferating and differentiating effects of three different growth factors on pluripotent mesenchymal cells and osteoblast like cells. J Orthop Surg Res 2007; 2: 27.
4. Carragee EJ, Hurwitz EL, Weiner BK,. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned. Spine J 2011; 11: 471-491.
5. Devine JG, Dettori JR, France JC, Brodt E, McGuire RA,. The use of rhBMP in spine surgery: Is there a cancer risk? Evid Based Spine Care J 2012; 3: 35-41.
6. Zara JN, Siu RK, Zhang X, Shen J, Ngo R, Lee M, Li W, Chiang M, Chung J, Kwak J, Wu BM, Ting K, Soo C,. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng Part A 2011; 17: 1389-1399.
7. Sailer HF, Weber FE,. Bone substitutes. Mund Kiefer Gesichtschir 2000; 4 (Suppl 1): S384-S391.
8. Yuan H, Fernandes H, Habibovic P, de Boer J, Barradas AMC, de Ruiter A, Walsh WR, van Blitterswijk CA, de Bruijn JD,. Osteoinductive ceramics as a synthetic alternative to autologous bone grafting. Proc Natl Acad Sci USA 2010; 107: 13614-13619.
9. Uludag H, D'Augusta D, Palmer R, Timony G, Wozney J,. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res 1999; 46: 193-202.
10. Guerado E, Fuerstenberg CH,. What bone graft substitutes should we use in post-traumatic spinal fusion? Injury 2011; 42 (Suppl 2): S64-S71.
11. Alam MI, Asahina I, Ohmamiuda K, Takahashi K, Yokota S, Enomoto S,. Evaluation of ceramics composed of different hydroxyapatite to tricalcium phosphate ratios as carriers for rhBMP-2. Biomaterials 2001; 22: 1643-1651.
12. Barradas AM, Yuan H, van Blitterswijk CA, Habibovic P,. Osteoinductive biomaterials: Current knowledge of properties, experimental models and biological mechanisms. Eur Cell Mater 2011; 21: 407-429; discussion 429.
13. Boix T, Gomez-Morales J, Torrent-Burgues J, Monfort A, Puigdomenech P, Rodriguez-Clemente R,. Adsorption of recombinant human bone morphogenetic protein rhBMP-2m onto hydroxyapatite. J Inorg Biochem 2005; 99: 1043-1050.
14. Gorbunoff MJ,. The interaction of proteins with hydroxyapatite. II. Role of acidic and basic groups. Anal Biochem 1984; 136: 433-439.
15. Gorbunoff MJ,. The interaction of proteins with hydroxyapatite. I. Role of protein charge and structure. Anal Biochem 1984; 136: 425-432.
16. Gorbunoff MJ, Timasheff SN,. The interaction of proteins with hydroxyapatite. III. Mechanism. Anal Biochem 1984; 136: 440-445.
17. Deligianni D, Korovessis P, Porte-Derrieu MC, Amedee J,. Fibronectin preadsorbed on hydroxyapatite together with rough surface structure increases osteoblasts' adhesion "in vitro": The theoretical usefulness of fibronectin preadsorption on hydroxyapatite to increase permanent stability and longevity in spine implants. J Spinal Disord Tech 2005; 18: 257-262.
18. Deligianni DD, Katsala N, Ladas S, Sotiropoulou D, Amedee J, Missirlis YF,. Effect of surface roughness of the titanium alloy Ti-6Al-4V on human bone marrow cell response and on protein adsorption. Biomaterials 2001; 22: 1241-1251.
19. Autefage H, Briand-Mesange F, Cazalbou S, Drouet C, Fourmy D, Goncalves S, Salles JP, Combes C, Swider P, Rey C,. Adsorption and release of BMP-2 on nanocrystalline apatite-coated and uncoated hydroxyapatite/beta-tricalcium phosphate porous ceramics. J Biomed Mater Res B Appl Biomater 2009; 91: 706-715.
20. Lin K, Xia L, Gan J, Zhang Z, Chen H, Jiang X, Chang J,. Tailoring the nano-structured surfaces of hydroxyapatite bioceramics to promote protein adsorption, osteoblast growth and osteogenic differentiation. ACS Appl Mater Interfaces 2013; 5: 8008-8017.
21. Hanseler P, Jung UW, Jung RE, Choi KH, Cho KS, Hammerle CH, Weber FE,. Analysis of hydrolyzable polyethylene glycol hydrogels and deproteinized bone mineral as delivery systems for glycosylated and non-glycosylated bone morphogenetic protein-2. Acta Biomater 2012; 8: 116-123.
22. Weber FE, Eyrich G, Gratz KW, Thomas RM, Maly FE, Sailer HF,. Disulfide bridge conformers of mature BMP are inhibitors for heterotopic ossification. Biochem Biophys Res Commun 2001; 286: 554-558.
23. Jung RE, Hammerle CH, Kokovic V, Weber FE,. Bone regeneration using a synthetic matrix containing a parathyroid hormone peptide combined with a grafting material. Int J Oral Maxillofac Implants 2007; 22: 258-266.
24. Jung RE, Weber FE, Thoma DS, Ehrbar M, Cochran DL, Hammerle CH,. Bone morphogenetic protein-2 enhances bone formation when delivered by a synthetic matrix containing hydroxyapatite/tricalciumphosphate. Clin Oral Implants Res 2008; 19: 188-195.
25. Exner HE,. A model stereological nomenclature. Acta Stereologica 1987; 6 (Suppl II): 179-184.
26. Louis-Ugbo J, Kim HS, Boden SD, Mayr MT, Li RC, Seeherman H, D'Augusta D, Blake C, Jiao A, Peckham S,. Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J Orthop Res 2002; 20: 1050-1059.
27. Ruppert R, Hoffmann E, Sebald W,. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996; 237: 295-302.
28. Tazaki J, Murata M, Akazawa T, Yamamoto M, Ito K, Arisue M, Shibata T, Tabata Y,. BMP-2 release and dose-response studies in hydroxyapatite and beta-tricalcium phosphate. Biomed Mater Eng 2009; 19: 141-146.
29. Steinmüller-Nethl D, Kloss FR, Najam-Ul-Haq M, Rainer M, Larsson K, Linsmeier C, Köhler G, Fehrer C, Lepperdinger G, Liu X, Memmel N, Bertel E, Huck CW, Gassner R, Bonn G,. Strong binding of bioactive BMP-2 to nanocrystalline diamond by physisorption. Biomaterials 2006; 27: 4547-4556.
30. Barradas AM, Fernandes HA, Groen N, Chai YC, Schrooten J, van de Peppel J, van Leeuwen JP, van Blitterswijk CA, de Boer J,. A calcium-induced signaling cascade leading to osteogenic differentiation of human bone marrow-derived mesenchymal stromal cells. Biomaterials 2012; 33: 3205-3215.
31. Jung RE, Glauser R, Scharer P, Hammerle CH, Sailer HF, Weber FE,. Effect of rhBMP-2 on guided bone regeneration in humans. Clin Oral Implants Res 2003; 14: 556-568.
32. Jung RE, Windisch SI, Eggenschwiler AM, Thoma DS, Weber FE, Hammerle CH,. A randomized-controlled clinical trial evaluating clinical and radiological outcomes after 3 and 5 years of dental implants placed in bone regenerated by means of GBR techniques with or without the addition of BMP-2. Clin Oral Implants Res 2009; 20: 660-666.